|
Posted: JUNE 26, 2007
Tissue
Welding Surgical Device Receives Approval in Russia,
Announces CSMG Technologies, Inc.
Corpus Christi, TX, June 26, 2007 -- CSMG Technologies,
Inc., (OTC Bulletin Board: CTUM
- News)
a technology management company, announced today the
Russian Federal Service of Health Care and Social Development
has approved the tissue welding electro surgery generator
and eight instruments for commercial use in its hospitals
and clinics. The approval is for a wide range of procedures
that this universal electrosurgical generator and its
instruments perform. The approval was issued to CSMG's
Ukraine partner International Association Welding "IAW"
on June 21, 2007.
"This is an achievement of monumental proportions
for IAW and CSMG. We expect to immediately begin implementing
our plans with IAW to manufacture, market and distribute
the tissue welding electrosurgery device and hand instruments
in both Ukraine and Russia. Russia and Ukraine have
a combined population of about 200 million people with
rich industrial, natural and scientific resources. A
world class team of surgeons, scientists, patent authors
and engineers are working on the technology at the E.O.
Paton Institute of Electric Welding in Kiev, Ukraine.
We have worked closely together over the years performing
R&D and clinical trials refining the technology
and surgical procedures to bring tissue welding technology
to its state. The Ukraine team along with our world
class medical device design, manufacturing, marketing
and management team in the US and the immediate filing
with the US FDA brings this unique medical device technology
to the forefront of the surgery industry. We believe
sales in Russia and Ukraine could reach $7 to $10 million
in 2008 and could grow at a rate of as much as 50% per
year for the next several years in these two rapidly
expanding medical markets," says Donald S. Robbins,
President and CEO.
"Getting approval in Russia opens wide opportunities
for commercialization of the tissue welding technology.
This is a major achievement for our international team's
hard work. Russian clinical work was performed by surgeons
at Hospital #1 in Moscow and Povlov University Hospital
in St. Petersburg, Russia. We were only able to bring
the live tissue welding technology from an idea stage
to its current level of a unique and revolutionary surgical
product because of the R&D funding and support provided
by our long time partner CSMG Technologies. We look
forward to continuing to work with CSMG in implementing
distribution throughout Russia and Ukraine," says
Dr. Alexander T. Zeluichenko, Director of the International
Association Welding, Kiev, Ukraine.
LTC's Frank D'Amelio added, "We are presently
moving from prototype to preproduction with our manufacturers
here in the United States. As a result of this news
we, will now be working with our Ukrainian and Russian
distribution partners to assess their demand requirements
and will fold their requirements and the timing thereof
into a worldwide production schedule. Live Tissue Connect,
Inc. (LTC) will continue to evaluate preproduction samples
of both our disposable RF-sealing instruments and our
bipolar generator, which are based on the aforementioned
technology, in July / August 2007. Adding Russian and
Ukrainian volume of these products to our production
plan will also occur during this same period."
"Welding technologies are victoriously walking
around the earth, underwater and in space. Nowadays
welding is being successfully used in medicine for bonding
damaged human tissue and restoring physiological function
of human organs," says academician B. E. Paton,
E. O. Paton Institute of Electric Welding, President
of National Academy of Science, Kiev, Ukraine.
CSMG owns the technology and exclusive world rights
to the live tissue bonding device through Live Tissue
Connect, Inc., a subsidiary corporation formed for the
development and exploitation of the platform technology.
LTC expects to complete the commercial hand instruments,
electro-cautery generator and other electrosurgery components
for the tissue welding system and begin product distribution
with IAW in the 4th quarter of 2007 for the Russian
and Ukrainian markets now that all necessary approvals
have been received in these countries.
About CSMG Technologies' Tissue Welding/Bonding
Technology
The LTC tissue bonding / welding device is a platform
technology that bonds and reconnects living soft biological
tissue through fusion without the use of foreign matter
in contrast with conventional wound closing devices
such as sutures, staples, sealant, or glues.
Surgeons at 27 Ukraine hospitals and clinics are using
the tissue welding/bonding technology in clinical trials.
They have completed more than 7,000 human surgeries
using more than 80 types of open and laparoscopic surgical
procedures, demonstrating the technology is universal
in its ability to repair soft biological tissue. These
surgeries included lung, neuro-surgery, nasal septum,
intestine, stomach, skin, gall bladder, liver, spleen,
blood vessels, nerves, alba linea, uterus, bladder,
gynecological, fallopian tube, ovary and testicles and
dura-matter. Cosmetic surgeries conducted with this
technology include breast reduction, breast implants,
mastopexy and abdominoplasty. The procedure involves
little or no scarring, while restoring the normal function
of the body organ or tissue.
The technology was invented and developed at the internationally
renowned E.O. Paton Institute of Electric Welding, National
Academy of Sciences of Ukraine, Kiev, Ukraine, headed
by Professor B.E. Paton. U.S., Australian, Canadian
and European Union patents have been issued, and additional
U.S. and foreign patents are pending, all owned by LTC.
About CSMG Technologies, Inc.
CSMG Technologies is a technology management company
that finances, owns, develops, licenses and markets
innovative advanced technologies and business opportunities
created in the Ukraine through a network of scientific
institutes and private organizations. CSMG is focused
on two primary subsidiaries, Live Tissue Connect, Inc.
and landfill gas processing.
For further information on CSMG Technologies and its
various subsidiaries, please visit our website at www.ctum.com.
Sign up to receive CSMG Technologies automated email
press releases and other notifications: Please go to
http://www.ctum.com/contact_information.html
and fill-in information.
This press release may contain forward-looking
information within the meaning of Section 21E of the
Securities Exchange Act of 1934 as amended (the Exchange
Act), including all statements that are not statements
of historical fact regarding the intent, belief or current
expectations of the company, its directors or its officers
with respect to, among other things: (i) the company's
financing plans; (ii) trends affecting the company's
financial condition or results of operations; (iii)
the company's growth strategy and operating strategy;
and (iv) the declaration and payment of dividends. The
words "may," "would," "will," "expect," "estimate,"
"anticipate," "believe," "intend" and similar expressions
and variations thereof are intended to identify forward-looking
statements. Investors are cautioned that any such forward-looking
statements are not guarantees of future performance
and involve risks and uncertainties, many of which are
beyond the company's ability to control, and that actual
results may differ materially from those projected in
the forward-looking statements as a result of various
factors.
CONTACT:
ROI Group Associates, Inc.
Michael Dodge, 212-495-0744
mdodge@roiny.com
or
Bob Giordano, 212-495-0201
CSMG Technologies, Inc. - 500 No. Shoreline # 701 no.
- Corpus Christi, TX 78471
Donald S. Robbins, President and CEO
361-887-7546
K. Bruce Jones
770-955-0409
|